Feb 5, 2021
Discontinuation of hormonal treatment quickly reduced meningioma risk
An observational cohort study from France observed a strong, dose-dependent association between long-term cyproterone acetate use and the risk of meningioma in girls and women and that risk dropped considerably once treatment was discontinued, researchers found.
Among 253,777 girls and women from 7-70 years of age who started taking cyproterone acetate a synthetic progesterone with potent antiandrogen activity between 2007 and 2014, high doses of the hormone were associated with a 7-fold incased risk of meningioma compared with relatively unexposed controls, Alain Weill, PhD, French National Health Insurance, Paris, and multi-center investigators reported in the
E-Mail
What The Study Did: This study quantified changes in the use of intravitreal (IVT) anti-vascular endothelial growth factors (anti-VEGF), the main treatment for retinal vascular abnormalities, since the COVID-19 pandemic started in France.
Authors: Sophie Billioti de Gage, Pharm.D., P.D., of EPI-PHARE, French National Agency for Medicines and Health Products Safety, French National Health Insurance in Saint-Denis, France, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/